Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Diabetes Mellitus, Type 1 1

Interventions

Specimen Handling 12 Magnetic Resonance Spectroscopy 11 Cyclophosphamide 10 Biological Therapy 9 Drug Therapy 8 Dexamethasone 7 Biopsy 7 antineoplaston A10 6 Nivolumab 6 Complementary Therapies 6 fludarabine 5 antineoplaston AS 2-1 5 aldesleukin 5 Ipilimumab 5 Etoposide 5 Doxorubicin 5 Cisplatin 5 atezolizumab 4 Vincristine 4 Surgical Procedures, Operative 4 Rituximab 4 Paclitaxel 4 Chemotherapy, Adjuvant 4 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4 venetoclax 3 olaparib 3 dexamethasone acetate 3 dexamethasone 21-phosphate 3 copanlisib 3 auricularum 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × NIH × golimumab × Clear all

NCT04729296 2021-12-02

Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 2 Withdrawn

Diabetes Mellitus, Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡